TNBC Biomarker/Target Discovery
Triple-Negative Breast Cancer
Preclinical (Mouse Studies)Active
Key Facts
About CogNano
CogNano uses alpaca-derived VHH antibodies and AI to discover novel biomarkers and drug targets for unmet medical needs in oncology.
View full company profileTherapeutic Areas
Other Triple-Negative Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| CB-839 (Telaglenastat) | Calithera Biosciences | Phase 2 |
| RejuverSen Antibody | Centenara Labs | Pre-Clinical |
| FlowVax BreastCA | Flow Pharma | Pre-clinical |
| Undisclosed circRNA Program | CircNova | Pre-clinical |
| Radiolabeled hTAB004 (Therapeutic) | OncoTAb | Preclinical |
| AI Predictor for TNBC | PathomIQ | Development/Validation |